US-based biotech company LB Pharmaceuticals has successfully raised significant funds through an initial public offering (IPO), breaking a dry spell in biotech IPOs for 2025. This achievement has caught the attention of the pharmaceutical and medical device industries. Meanwhile, the European Society of Cardiology (ESC) Congress remains a key event where experts look for the latest advancements in heart health. In other news, AbbVie has extended the patent protection for its popular autoimmune drug Rinvoq (upadacitinib) until 2037, ensuring its strong position in the market. The UK, however, faces concerns about losing its leadership in life sciences due to investments shifting to other regions. US President Donald Trump is taking action against pharmaceutical companies and social media influencers involved in misleading health claims. Novo Nordisk plans to cut 9,000 jobs as part of cost-saving measures, struggling with market challenges. The US government has ordered $56 million worth of mpox and smallpox vaccines to improve public health readiness. Novo Nordisk’s decision to lower the price of its blockbuster drug semaglutide may slow the transition of patients to alternative treatments. US Health Secretary Robert F Kennedy Jr. is facing questions about changes to vaccine guidelines and recent staffing changes. The European Medicines Agency (EMA) has issued a warning about the rise of illegal medicines being sold as legitimate treatments.